Follow-The-Filings

Security · featured owners

FDMT 4D Molecular Therapeutics In

COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.4%
  • $4M
  • 1 add

Who owns this now

Largest portfolio weights among featured holders · max 0.4% (James Silverman - Opaleye...) · not free-float ownership

  1. James Silverman add 0.40%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
James Silverman - Opaleye Management 2026 Q2 0.40% Add +197.8% 334,437 $4M history

1 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 14 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02 Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
8-K 1.01,2.03 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 3.02,9.01 Filing Doc
8-K 2.02,5.02 Filing Doc
8-K 8.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 25 shown

Filed Form Detail Links
4 Period Aug 19, 2026 Filing Doc
4 Period Aug 13, 2026 Filing Doc
4 Period Aug 4, 2026 Filing Doc
4 Period Aug 3, 2026 Filing Doc
4 Period Jul 9, 2026 Filing Doc
4 Period Jun 30, 2026 Filing Doc
4 Period Jun 23, 2026 Filing Doc
4 Period Jun 22, 2026 Filing Doc
4 Period Jun 17, 2026 · 7 forms Filing Doc
4 Period Jun 1, 2026 Filing Doc
4 Period Mar 25, 2026 · 3 forms Filing Doc
4 Period Mar 20, 2026 Filing Doc
4 Period Jan 5, 2026 Filing Doc
4 Period Dec 20, 2025 Filing Doc
4 Period Dec 16, 2025 Filing Doc
4 Period Dec 12, 2025 Filing Doc
4 Period Dec 9, 2025 Filing Doc

Updated 6 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $20.72M $37,000 $85.21M
Net income -$100.84M -$160.87M -$140.11M
Net margin * -486.6% -434778.4% -164.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $296.59M $434.93M $413.13M
Total non-current assets * $43.3M $125.45M $153.58M
Total assets $339.89M $560.38M $566.71M
Total current liabilities $18.95M $29.15M $43.98M
Total non-current liabilities * $13.11M $20.63M $17.06M
Total equity $307.83M $510.61M $505.66M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$75.79M -$134.58M -$109.08M
Cash from investing $115.72M -$302.44M -$92.97M
Cash from financing $156.83M $337.25M $112.96M
Net change in cash $196.76M -$99.77M -$89.1M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders